Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Jul 29, 2020

SELL
$7.25 - $11.75 $399,221 - $647,013
-55,065 Closed
0 $0
Q1 2020

Apr 30, 2020

BUY
$4.06 - $10.64 $223,563 - $585,891
55,065 New
55,065 $437,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Chartwell Investment Partners, LLC Portfolio

Follow Chartwell Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chartwell Investment Partners, LLC with notifications on news.